Skip to main content

Page of 2 next disabled
and
  1. No Access

    Article

    MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs

    Metastasis is the cause for 90% of cancer-related mortalities. Identification of genetic drivers promoting dissemination of tumor cells may provide opportunities for novel therapeutic strategies. We previously...

    Joshua Kapere Ochieng, Samrat T. Kundu, Rakhee Bajaj, B. Leticia Rodriguez in Oncogene (2020)

  2. Article

    Open Access

    Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion

    Tumor extracellular matrix has been associated with drug resistance and immune suppression. Here, proteomic and RNA profiling reveal increased collagen levels in lung tumors resistant to PD-1/PD-L1 blockade. A...

    David H. Peng, Bertha Leticia Rodriguez, Lixia Diao, Limo Chen in Nature Communications (2020)

  3. No Access

    Article

    IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion

    Non-small cell lung cancer (NSCLC) is the deadliest form of cancer worldwide, due in part to its proclivity to metastasize. Identifying novel drivers of invasion and metastasis holds therapeutic potential for ...

    Rakhee Bajaj, Samrat T. Kundu, Caitlin L. Grzeskowiak, Jared J. Fradette in Oncogene (2020)

  4. No Access

    Article

    18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer

    Enhanced tumor glycolytic activity is a mechanism by which tumors induce an immunosuppressive environment to resist adoptive T cell therapy; therefore, methods of assessing intratumoral glycolytic activity are...

    Kyle G. Mitchell, Behrang Amini, Yunfei Wang in Cancer Immunology, Immunotherapy (2020)

  5. Article

    Open Access

    Comprehensive T cell repertoire characterization of non-small cell lung cancer

    Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NS...

    Alexandre Reuben, Jiexin Zhang, Shin-Heng Chiou in Nature Communications (2020)

  6. Article

    Open Access

    ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer

    Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, due in part to the propensity of lung cancer to metastasize. Aberrant epithelial-to-mesenchymal transition (EMT) is a ...

    Roxsan Manshouri, Etienne Coyaud, Samrat T. Kundu, David H. Peng in Nature Communications (2019)

  7. Article

    Open Access

    A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer

    Lung cancer is the foremost cause of cancer related deaths in the U.S. It is a heterogeneous disease composed of genetically and phenotypically distinct tumor cells surrounded by heterotypic cells and extracel...

    Aparna Padhye, Christin Ungewiss, Jared J. Fradette in Scientific Reports (2019)

  8. Article

    Open Access

    TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins

    Metastatic lung cancer is the leading cause of cancer-associated mortality worldwide, therefore necessitating novel approaches to identify specific genetic drivers for lung cancer progression and metastasis. W...

    Samrat T. Kundu, Caitlin L. Grzeskowiak, Jared J. Fradette in Nature Communications (2018)

  9. Article

    Open Access

    In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer

    Genetic aberrations driving pro-oncogenic and pro-metastatic activity remain an elusive target in the quest of precision oncology. To identify such drivers, we use an animal model of KRAS-mutant lung adenocarcino...

    Caitlin L. Grzeskowiak, Samrat T. Kundu, **ulei Mo in Nature Communications (2018)

  10. Article

    Open Access

    Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

    The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor t...

    Edwin R. Parra, Pamela Villalobos, Carmen Behrens in Journal for ImmunoTherapy of Cancer (2018)

  11. Article

    Open Access

    Pan-urologic cancer genomic subtypes that transcend tissue of origin

    Urologic cancers include cancers of the bladder, kidney, prostate, and testes, with common molecular features spanning different types. Here, we show that 1954 urologic cancers can be classified into nine majo...

    Fengju Chen, Yiqun Zhang, Dominick Bossé, Aly-Khan A. Lalani in Nature Communications (2017)

  12. Article

    Open Access

    Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

    While clinical outcomes following immunotherapy have shown an association with tumor mutation load using whole exome sequencing (WES), its clinical applicability is currently limited by cost and bioinformatics...

    Jason Roszik, Lauren E. Haydu, Kenneth R. Hess, Junna Oba, Aron Y. Joon in BMC Medicine (2016)

  13. Article

    Open Access

    A genetic cell context-dependent role for ZEB1 in lung cancer

    The Zinc-finger E-box-binding Homeobox-1 (ZEB1) is a transcription factor that promotes epithelial–mesenchymal transition (EMT) and acts as an oncogene in KRAS-mutated lung cancer models. Here we report that ZEB1...

    Ting Zhang, Lixia Guo, Chad J. Creighton, Qiang Lu, Don L. Gibbons in Nature Communications (2016)

  14. Article

    Open Access

    The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL

    Tumor cell metastasis is a complex process that has been mechanistically linked to the epithelial-mesenchymal transition (EMT). The double-negative feedback loop between the microRNA-200 family and the Zeb1 tr...

    Christin Ungewiss, Zain H. Rizvi, Jonathon D. Roybal, David H. Peng in Scientific Reports (2016)

  15. No Access

    Article

    Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

    Immunosuppression of tumour-infiltrating lymphocytes (TIL) is a common feature of advanced cancer, but its biological basis has remained obscure. We demonstrate here a molecular link between epithelial-to-mese...

    Limo Chen, Don L. Gibbons, Sangeeta Goswami, Maria Angelica Cortez in Nature Communications (2014)

  16. No Access

    Chapter

    The Role of MicroRNAs in Lung Cancer Development, Progression, and Metastasis

    Lung cancer is the leading cause of cancer death globally. Although molecularly targeted agents have made small advances in the treatment options for patients, the overall 5-year survival rate has changed litt...

    Don L. Gibbons, Zain H. Rizvi in MicroRNAs in Cancer Translational Research (2011)

  17. No Access

    Article

    Conformational change and protein–protein interactions of the fusion protein of Semliki Forest virus

    Fusion of biological membranes is mediated by specific lipid-interacting proteins that induce the formation and expansion of an initial fusion pore. Here we report the crystal structure of the ectodomain of th...

    Don L. Gibbons, Marie-Christine Vaney, Alain Roussel, Armelle Vigouroux in Nature (2004)

  18. Chapter

    Specific Roles for Lipids in Virus Fusion and Exit Examples from the Alphaviruses

    Margaret Kielian, Prodyot K. Chatterjee in Fusion of Biological Membranes and Related… (2002)

Page of 2 next disabled